Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Ozempic has been a hot topic in Hollywood with stars either admitting to using the diabetes drug for weight loss or staunchly ...

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...

The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...

X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Your doctor broke news you didn’t want to hear: you have prediabetes, a condition where blood sugar is elevated, but not high ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...